Foley Todd
SEC Form 4 insider trading activity
Foley Todd has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Jan 14, 2026.
On the most recent filing, Foley Todd is listed as Director, 10% Owner at Aktis Oncology, Inc. Inside the rolling window, Foley Todd reported 1 open-market purchase totaling $4.2M in AKTS and no open-market sales.
Companies traded
Other insiders at AKTS
Insider Buying
$4.2M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Foley Todd made?
Foley Todd has filed 1 SEC Form 4 filing (4 transaction rows) across 1 company since 2026.
Which companies does Foley Todd trade?
Foley Todd has filed SEC Form 4 disclosures for 1 company, including AKTS.
When was Foley Todd's most recent SEC Form 4 filing?
Foley Todd's most recent SEC Form 4 filing on Tracefour is dated Jan 14, 2026.
What is Foley Todd's total buy and sell value in the current window?
Inside the rolling retention window, Foley Todd bought $4.2M and sold $0 based on SEC Form 4 filings.
What was Foley Todd's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 232,870 AKTS shares on 2026-01-12, worth $4.2M, per SEC Form 4 filings.